Clinical Evaluation on 12-week Administration of Seratrodast, a Thromboxane A2 Antagonist, in Perennial Allergic Rhinitis.
|
Accession number;99A0315575
|
| Title;Clinical Evaluation on 12-week Administration of Seratrodast, a Thromboxane A2 Antagonist, in Perennial Allergic Rhinitis. |
| Author;
YAJIN KOJI
(Hiroshima Univ., Sch. of Med.)
HIRAKAWA KATSUHIRO
(Hiroshima Univ., Sch. of Med.)
TAKEBAYASHI SHUBUN
(Hiroshima Prefect. Hosp.)
OMURA RYOJI
(Hiroshimaken Kosei Nogyo Kyodokumiai Rengokai Hiroshima Sogo Byoin)
YAMASHITA TAKASHI
(Hirosima Prefect. Welf. Fed of Agric. Co-op., Onomichi General Hosp.)
WATANABE HIROSHI
(Chugoku Rosai Hosp.)
TADA WATARU
(Mazda Hosp.)
NIKAIDO MASAFUMI
(JR Hiroshima Railway Hosp.)
NAGASAWA AKIRA
(Koritsumiyoshichuobyoin)
|
Journal Title;Journal of Clinical Therapeutics & Medicines
|
Journal Code:Y0906A
|
ISSN:0910-8211
|
|
VOL.15;NO.2;PAGE.373-388(1999)
|
| Figure&Table&Reference;FIG.1, TBL.15, REF.10 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;A thromboxane A2 antagonist, AA-2414 (seratrodast), at 80mg/day was orally given once daily after evening meal to the patients with perennial allergic rhinitis with severity of moderate to severe, for 12 weeks, a target day, to 24 weeks when possible, to determine its efficacy and safety in a long-term period. 1) The total number of subjects was 19. Twelve completed 12-week administration or longer, and 2 of them received administration for 24 weeks. 2) Improvement rate in nasal symptoms (at the final evaluation), primary end point: "moderate improvement" or better was 52.9% (9/17). 3) Improvement rate over the time course: "moderate improvement" or better were 52.9% (9/17), 57.1% (8/14), and 50.0% (6/12) for 4, 8, and 12 weeks, respectively. 4) Improvement rate classified by symptoms (at the final evaluation): "moderate improvement" or better were 43.8% (7/16) for nasal obstruction, 25.0% (4/16) for nasal discharge, and 25.0% (4/16) for sneezing, showing high improvement especially for nasal obstruction. 5) Improvement rate in nasal obstruction over the time course: "moderate improvement" or letter were 50.0% (8/16), 50.0% (7/14), and 50.0% (6/12) for 4, 8, and 12 weeks, respectively. 6) Safety: adverse events where causality with the agent could not be denied included increased urinary frequency, pruritus and anthema, and increases in GPT, GOP, .GAMMA.-GTP and BUN, each in one case. They all were slight, and not clinically significant. These results suggest that AA-2414 appears to be highly effective in treating perennial allergic rhinitis and safe in a long-term period. (author abst.) |
|
|
|
Related Articles;
|
|
